HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,662,681 | +3.5% | 148,238 | -2.3% | 0.35% | +7.7% |
| Q2 2023 | $5,473,476 | -1.6% | 151,746 | -47.9% | 0.33% | -8.2% |
| Q1 2023 | $5,562,966 | +77747.3% | 291,040 | +131.8% | 0.36% | -29.0% |
| Q4 2022 | $7,146 | -99.9% | 125,582 | -0.0% | 0.50% | +37.7% |
| Q3 2022 | $4,967,000 | -42.2% | 125,619 | -35.7% | 0.36% | -33.4% |
| Q2 2022 | $8,597,000 | -13.2% | 195,391 | -21.4% | 0.54% | +5.2% |
| Q1 2022 | $9,909,000 | +4.3% | 248,461 | +5.1% | 0.52% | +12.9% |
| Q4 2021 | $9,502,000 | -9.8% | 236,301 | -8.7% | 0.46% | -12.9% |
| Q3 2021 | $10,534,000 | -7.2% | 258,947 | +3.6% | 0.53% | -7.4% |
| Q2 2021 | $11,351,000 | +10.4% | 249,970 | +1.4% | 0.57% | +6.0% |
| Q1 2021 | $10,280,000 | -1.9% | 246,575 | +0.4% | 0.54% | +3.3% |
| Q4 2020 | $10,484,000 | -22.9% | 245,476 | -52.6% | 0.52% | -24.7% |
| Q3 2020 | $13,601,000 | -3.6% | 517,526 | -1.7% | 0.69% | -8.2% |
| Q2 2020 | $14,112,000 | – | 526,389 | – | 0.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |